ISRCTN46343886已完成Unknown
Phase 1 trial: CA38951
Millicent Pharma Limited0 个研究点目标入组 36 人开始时间: 2024年2月14日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
排除标准
- •The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
研究者
相似试验
进行中（未招募）
1 期
Phase I trial: QSC206159Healthy volunteersISRCTN51392723Oxilio Limited12
进行中（未招募）
1 期
Phase I trial - 2021-006930-37The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has endedISRCTN15751828Omeros Corporation (United States)12
已完成
1 期
Phase 1 Trial: CA38132Healthy volunteersISRCTN67246142Pliant (United States)51
进行中（未招募）
1 期
Phase I trial, Quotient code: QSC301137, Sponsor code: LMNL6511C1001The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.ISRCTN46791858iminal BioSciences (United Kingdom)88
进行中（未招募）
1 期
Phase 1 trial, HMR code: 21-004The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.Not SpecifiedISRCTN12926361Gedeon Richter Plc104